Live Breaking News & Updates on Opaleye Management

Stay updated with breaking news from Opaleye management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Harrow, Inc. (NASDAQ:HROW) Short Interest Down 9.5% in May

Harrow, Inc. (NASDAQ:HROW – Get Free Report) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 4,980,000 shares, a decline of 9.5% from the April 30th total of 5,500,000 shares. Based on an average daily volume of 510,400 shares, the […] ....

Markl Baum , Craig Hallum , Pricet Rowe Associates Inc , Surface Ophthalmics Inc , Pharmaceuticals Inc , Opaleye Management Inc , Harrow Inc , Vanguard Group Inc , Harrow Health Inc , Eton Pharmaceuticals Inc , Get Free Report , Street Capital , Opaleye Management , Capital Management , Financial Markets , Stock Down , Surface Ophthalmics , Melt Pharmaceuticals , Eton Pharmaceuticals , Harrow Daily ,

iBio (NYSE:IBIO) Earns Buy Rating from Analysts at Chardan Capital

Chardan Capital assumed coverage on shares of iBio (NYSE:IBIO – Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $5.00 price target on the stock. Separately, StockNews.com started coverage on iBio in a research note on Saturday, April 20th. They issued a sell rating for the […] ....

United States , Bio Inc , Ikarian Capital , Opaleye Management Inc , Chardan Capital , Free Report , Bio Trading Down , Get Free Report , Opaleye Management , Bio Daily ,

Harrow (NASDAQ:HROW) Shares Down 5.8%

Shares of Harrow, Inc. (NASDAQ:HROW – Get Free Report) traded down 5.8% on Wednesday . The company traded as low as $17.45 and last traded at $17.49. 215,167 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 464,695 shares. The stock had previously closed at $18.56. Analyst Upgrades […] ....

Craig Hallum , Markl Baum , Jump Financial , Securities Exchange Commission , Opaleye Management Inc , Kennedy Capital Management , Harrow Company Profile , Stifel Financial Corp , China Universal Asset Management Co , Surface Ophthalmics Inc , Eton Pharmaceuticals Inc , Harrow Health Inc , Harrow Inc , Pharmaceuticals Inc , Get Free Report , Trading Down , Opaleye Management , Exchange Commission , Capital Management , Financial Corp , China Universal Asset Management , Universal Asset Management , Surface Ophthalmics , Melt Pharmaceuticals , Eton Pharmaceuticals , Harrow Daily ,

Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells $100,980.00 in Stock

Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) major shareholder Opaleye Management Inc. sold 33,000 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $3.06, for a total transaction of $100,980.00. Following the sale, the insider now directly owns 124,250 shares of the company’s […] ....

Opaleye Management Inc , Exchange Commission , Ikarian Capital , Securities Exchange Commission , Protara Therapeutics Company Profile , Protara Therapeutics Inc , Protara Therapeutics , Get Free Report , Opaleye Management , Free Report , Protara Therapeutics Daily ,

Analysts Offer Predictions for Harrow, Inc.'s Q2 2024 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW – Free Report) – B. Riley dropped their Q2 2024 earnings per share (EPS) estimates for Harrow in a research report issued to clients and investors on Tuesday, May 14th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.25) per share for the quarter, down from their previous […] ....

Markl Baum , Craig Hallum , Jump Financial , Harrow Health Inc , Rice Hall James Associates , Harrow Inc , Securities Exchange Commission , Kennedy Capital Management , Stifel Financial Corp , Pharmaceuticals Inc , Eton Pharmaceuticals Inc , Surface Ophthalmics Inc , Opaleye Management Inc , Free Report , Get Free Report , Capital Management , Financial Corp , Rice Hall James , Opaleye Management , Exchange Commission , Surface Ophthalmics , Melt Pharmaceuticals , Eton Pharmaceuticals , Harrow Daily ,